GALECTIN THERAPEUTICS INC. - COMMON STOCK

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2025 Congress

15 Apr 2025 08:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update

31 Mar 2025 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial

18 Feb 2025 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at the 2025 MASH-TAG Conference

10 Jan 2025 08:00:00 By Nasdaq GlobeNewswire

NetDania - New 12 months Low: GALECTIN THERAPEUTICS INC. - COMMON STOCK

20 Dec 2024 10:16:30 By NetDania Notify

Galectin Therapeutics Announces Top-Line Results of NAVIGATE Clinical Trial Evaluating Belapectin in Patients with Cirrhotic Portal Hypertension Caused by MASH

20 Dec 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Presents Three Abstracts at the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

18 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update

14 Nov 2024 08:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting

15 Oct 2024 08:00:01 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference

30 Sep 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

03 Sep 2024 08:30:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update

13 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer

01 Aug 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Present at the European Association for the Study of the Liver (EASL) 2024 Congress

04 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update

15 May 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference

13 May 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis

09 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development

12 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update

13 Nov 2023 08:45:52 By Nasdaq GlobeNewswire